Approval · Notice of Compliance 9027 · 2007
EXELON: Notice of Compliance 9027
Issued September 17, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9027
- Date
- September 17, 2007
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: symptomatic treatment of patients with idiopathic parkinson's disease, and mild to moderate dementia, with onset at least 2 years after the initial diagnosis of parkinson's disease, and in whom other causes of dementia have been ruled out, and other revisions to the product monograph
- Therapeutic class
- Cholinesterase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON | Not yet assigned | — |
Medicinal ingredients
- RIVASTIGMINE HYDROGEN TARTRATE 1.5 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 3 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 4.5 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 6 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 2 MG per ML